Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014443 · ClinicalTrials.gov registry record · Phase 2
Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
A Phase 2 study, sponsored by Rush University Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00014443 is a Phase 2 study that was terminated before completion, run by Rush University Medical Center. The registered enrollment target is 5 participants.
The verdict
NCT00014443, a Phase 2 study, was terminated before completion, sponsored by Rush University Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of combining topotecan and thalidomide in treating patients who have recurrent or refractory malignant glioma.
Interventions
- DRUG topotecan hydrochloride
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2000-08 |
| Est. Completion | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014443
The ClinicalTrials.gov registry entry for NCT00014443 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which topotecan hydrochloride is the first listed.
NCT00014443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00014443 about?
NCT00014443 is a clinical study titled "Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of combining topotecan and thalidomide in treating...
What is the current status of trial NCT00014443?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2000-08. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00014443?
The interventions under investigation include: topotecan hydrochloride (DRUG), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00014443?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.